Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies

Blurring the boundary between innate and adaptive immune system, natural killer (NK) cells are widely recognized as potent anti-leukemia mediators. Alloreactive donor NK cells have been shown to improve the outcome of allogeneic stem cell transplantation for leukemia. In addition, in vivo transfer of NK cells may soon reveal an important therapeutic tool for leukemia, if tolerance to NK-mediated anti-leukemia effects is overcome. This will require, at a minimum, the ex vivo generation of a clinically safe NK cell product containing adequate numbers of NK cells with robust anti-leukemia potential. Ideally, ex vivo generated NK cells should also have similar anti-leukemia potential in different patients, and be easy to obtain for convenient clinical scale-up. Moreover, optimal clinical protocols for NK therapy in leukemia and other cancers are still lacking. These and other issues are being currently addressed by multiple research groups. This review will first describe current laboratory NK cell expansion and differentiation techniques by separately addressing different NK cell sources. Subsequently, it will address the mechanisms known to be responsible for NK cell alloreactivity, as well as their clinical impact in the HSCT setting. Finally, it will briefly provide insight on past NK-based clinical trials.

Abstract licence: CC BY

• Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse · 2022

• CD56 in the Immune System: More Than a Marker for Cytotoxicity? · 2017

• Selection and expansion of natural killer cells for NK cell-based immunotherapy · 2016

• The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer · 2015

• Advantages and applications of CAR-expressing natural killer cells · 2015

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.